scholarly journals Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis

2014 ◽  
Vol 4 (8) ◽  
pp. e239-e239 ◽  
Author(s):  
J Lu ◽  
◽  
J Lu ◽  
W Chen ◽  
Y Huo ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Treatment Outcome ◽  
Clinical Features ◽  
Chinese Patients ◽  
Newly Diagnosed ◽  
Multicenter Analysis

Bortezomib in Combination with Dexamethasone and Subsequent Thalidomide for Newly-Diagnosed Multiple Myeloma in Chinese Patients.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4827-4827
Author(s):  
Zhen Cai ◽  
Weiyan Zheng ◽  
Guoqing Wei ◽  
Xiujin Ye ◽  
Jingsong He ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Overall Response Rate ◽  
Response Rate ◽  
Staging System ◽  
Primary Treatment ◽  
Chinese Patients ◽  
Newly Diagnosed ◽  
Overall Response ◽  
International Staging System ◽  
Grade 3

Abstract Background: Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (MM) with an overall response rate of 92% and a CR rate of 18% (Alexanian et al, Hematology12(3):235–239, 2007), but this regimen has not been reported in Chinese patients. We now report our experience with this combination. Objectives: To investigate the efficacy and safety of bortezomib in combination of dexamethasone plus subsequent thalidomide as primary treatment for MM. Patients and Method: Between June 2006 and August 2007, 11 consecutive newly-diagnosed patients with symptomatic MM were treated with bortezomib at 1.3 mg/m2 IV on days 1, 4, 8 and 11, dexamethasone at 20 mg/m2 IV daily on the day of bortezomib and the day after. All patients received daily oral thalidomide that was escalated from 100 mg to 200 mg. Seven of 11 patients were male and 4 were female. Median age was 57 years (range 47–86). Seven of 11 patients were stage 2 according to the International Staging System, 4 out of 11 patients were stage 3. Eleven patients received a median of 2 cycles of therapy (range 1–6). The Blade criteria were used for response evaluation. Toxicities were evaluated according to the NCI Common Toxicity Criteria version 3. Results: Nine out of 11 patients (82%) achieved PR and 2 (18%) achieved CR; therefore the overall response rate was 100%. With a median follow-up duration of 5 months (1– 14 months), no patients died. Grade 3–4 toxicities included fatigue (3/11), thrombocytopenia (3/11), diarrhea (3/11) and orthostatic hypotension (2/11). Grade 2 neuropathy occurred in 3 out of 11 patients, herpes zoster occurred in 3 out of 11 patients. Routine anticoagulation or anti-thrombosis was not used. There was no DVT/PE in 11 patients. Conclusion: Our preliminary experience indicated that bortezomib-dexamethasone-thalidomide is highly effective in newly-diagnosed MM. Grade 3 and 4 toxicities were rare after median 2 cycles of therapy. The relative lower rates of neuropathy and DVT/PE in this report with Chinese MM patients are being cautiously observed.

Once Weekly Bortezomib Plus Dexamethasone in Newly Diagnosed Multiple Myeloma: A Preliminary Study in Chinese Patients

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 5128-5128
Author(s):  
Yadan Wang ◽  
Yu Hu ◽  
Lisha Ai ◽  
Bhuveshwarnath Gowrea ◽  
Guohui Cui ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Treatment Group ◽  
Conflicts Of Interest ◽  
Rest Period ◽  
Chinese Patients ◽  
Weekly Schedule ◽  
Newly Diagnosed ◽  
Weekly Treatment ◽  
Grade 3

Abstract Abstract 5128 Introduction: Bortezomib has become a cornerstone in the management of multiple myeloma (MM) and the currently accepted practice is a twice weekly administration at 1.3mg/m2. Recently, several studies have demonstrated a successful treatment with the modified Bortezomib schedule in refractory or elderly newly diagnosed MM. These previous studies suggest that, given at weekly intervals, Bortezomib remains equally efficacious and may even improve tolerability. We here present our institution's experience where we retrospectively compare the efficacy and toxicity parameters between once weekly (1.6mg/m2) and twice weekly (1.3mg/m2) schedule of Bortezomib plus Dexamethasone in newly diagnosed, untreated MM patients. Methods: The once weekly schedule consisted of 5-week cycle of which Bortezomib plus Dexamethsone was administered during the first 4 weeks as follows: Bortezomib 1.6mg/m2 intravenously on days 1, 8, 15, 22 and Dexamethsone 20mg intravenously on days 1–2, 8–9, 15–16 and 22–23 followed by a 12-day rest period. The twice weekly schedule consisted of 3-week cycle as follows: Bortezomib 1.3mg/m2 intravenously on days 1, 4, 8, 11 and Dexamethsone 20mg intravenously on days 1–2, 4–5, 8–9 and 11–12 followed by a 9-day rest period. We retrospectively collected data from Jan 2009 to Dec 2010 of 37 patients with newly diagnosed MM who were either treated with once weekly schedule (n =13) or twice weekly schedule (n = 24). Allocation of patients to their respective treatment group was not randomized but rather on the basis of their means, after they were made fully aware that the once weekly schedule was still under evaluation. Results: The median age was similar between two schedules (53 years vs. 54.5 years, P=0.674). Both treatment groups received a median number of two cycles of chemotherapy. The median follow-up was also similar, being 12 months (range, 4–19) in the once weekly treatment group and 10.5 months (range, 2–19)in the twice weekly treatment group. In the standard twice weekly schedule, the overall response rate of 74.9% including 2(8.3%) CR, 8(33.3%) VGPR and 8(33.3%) PR, while 2(8.3%) patients had stable disease (SD) and 3(12.5%) had progressive disease (PD). Among the patients in the weekly schedule, 10 of 13 patients (77.0%) achieved at least PR with 30.8% at least VGPR. In addition, SD was observed in 1 patient (7.7%) and PD in another 1 patient (7.7%). The responses to treatment were not found to be statistically significant different in our study when comparing the once weekly schedule to the twice weekly schedule. The median time to the best response was 2 cycles (range,2–4) in the once weekly schedule as compared with 2.5 cycles (range,2–4) in the twice weekly schedule (P=0.564). The median survival was not reached in either schedule since the follow-up was not long enough. The median progression free survival (PFS) and duration of response (DOR) of the weekly schedule did not differ significantly from that of the twice weekly schedule (8 months vs. 10 months, P=0.545 and 6 months vs. 7 months, P=0.467; respectively). After a median follow-up of 12 months (range, 2–19), 2 patients (15.4%) in the weekly schedule and 4 patients (16.6%) in the twice weekly schedule had died (P=0.723) thus mortality in the two groups did not differ significantly. Over grade 3 of gastrointestinal symptoms were similar in the once weekly (16%) and twice weekly (20.5%) schedules. Peripheral sensory neuropathy was reported more frequently in the twice weekly schedule, including grade 1 in 4 patients (17%), grade 2 in 4 patients (17%), grade 3 in 3 patients (12.5%), and grade 4 in 1 patient (4%). While grade 1 neuropathy in 2 patients (15%), grade 2 in 1 patient (8%), grade 3 in 1 patient (8%) were reported in the weekly schedule and all had resolved within two months. All grade 3 and 4 hematologic toxic effects were more frequent in the twice- weekly schedule than in the weekly schedule (75% vs. 54%), as was over grade 2 of herpes zoster (16.5% vs. 8%). Incidence of over grade 2 rash remained low and was similar in the two schedules (both 8%). However the difference between the two schedules was not statistical significantly. Conclusions: Our study provides additional evidence that the once weekly Bortezomib (1.6mg/m2) plus Dexamethasone schedule is active and well tolerated in the treatment of patients with newly-diagnosed multiple myeloma, with the similar efficacy and lesser toxicity compared with the twice weekly schedule. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Association of Serum Calcium Levels With Renal Impairment and All-cause Death in Chinese Patients With Newly Diagnosed Multiple Myeloma: A Cross-sectional, Longitudinal Study

2020 ◽  
Author(s):  
Jun Cheng ◽  
Wen Zhang ◽  
Yi Zhao ◽  
Xiayu Li ◽  
Rong Lv ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Renal Impairment ◽  
Serum Calcium ◽  
Calcium Level ◽  
Serum Calcium Level ◽  
Cox Regression ◽  
Chinese Patients ◽  
Newly Diagnosed ◽  
Cross Sectional ◽  
Baseline Serum

Abstract Background: A number of studies have shown that serum calcium has a crucial role in many types of cancers. However, few studies have determined the association between serum calcium levels and renal impairment (RI) and all-cause death in Chinese patients with multiple myeloma (MM).Methods: Two hundred forty-six of 566 participants who were followed for > 6 months from a MM cohort at our institution between January 2011 and June 2017 were eligible for the retrospective study. A generalized additive model and smooth curve fitting were conducted to investigated the cross-sectional relationship between serum calcium level and RI and eGFR at baseline；Multivariate-adjusted Cox regression models were fitted to assess associations between baseline serum calcium levels and onset of end-stage renal disease(ESRD) or death in patients with MM followed for > 6 months.Results: Using the IMWG criteria,162 of 566 patients (28.6%) with newly diagnosed MM presented with RI . The mean duration of follow-up was 26.64 months. Twenty-one patients (8.54%) died and 28 patients（11.52%）had ESRD.The serum calcium level was independently associated with the occurrence of MM-related RI. There was a non-linear relationship between the serum calcium level and the presence of RI in patients with MM in the cross-sectional analysis of the baseline data. Cox regression analysis showed that baseline serum calcium levels were consistently associated with a higher risk of all-cause death after adjustment for various clinical and laboratory factors, but were not associated with the occurrence of ESRD. When patients were categorized into 2 groups according to baseline mean serum calcium level, deaths occurred in 13 patients (15.1%) with mean serum calcium level > 2.44 mmol/L compared to 8 patients (5.0%) with mean serum calcium level < 2.44 mmol/L (p < 0.05); Eighteen patients (11.46%) with a mean serum calcium level < 2.44 mmol/L progressed to ESRD compared to 13 patients (11.6%) with a serum calcium level > 2.44 mmol/L (p > 0.05).Conclusions: This observational study showed that there was a non-linear relationship between the serum calcium level and the occurrence of RI. An elevated baseline calcium level can predict all-cause death in patients with MM, but cannot predict the occurrence of ESRD, suggesting that the serum calcium level may serve as a useful clinical biomarker for the survival rate of patients with MM followed for > 6 months. Additional data from larger prospective longitudinal studies are required to validate our findings.

scholarly journals Association of Serum Calcium Levels with Renal Impairment and All-Cause Death in Chinese Patients with Newly Diagnosed Multiple Myeloma: A Cross-Sectional, Longitudinal Study

2020 ◽  
Author(s):  
Jun Cheng ◽  
Wen Zhang ◽  
Yi Zhao ◽  
Xiayu Li ◽  
Rong Lv ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Renal Impairment ◽  
Serum Calcium ◽  
Calcium Level ◽  
Serum Calcium Level ◽  
Cox Regression ◽  
Chinese Patients ◽  
Newly Diagnosed ◽  
Cross Sectional ◽  
Baseline Serum

Abstract Background: A number of studies have shown that serum calcium has a crucial role in many types of cancers. However, few studies have determined the association between serum calcium levels and renal impairment (RI) and all-cause death in Chinese patients with multiple myeloma (MM).Methods: Two hundred forty-six of 566 participants who were followed for > 6 months from a MM cohort at our institution between January 2011 and June 2017 were eligible for the retrospective study. A generalized additive model and smooth curve fitting were conducted to investigated the cross-sectional relationship between serum calcium level and RI and eGFR at baseline；Multivariate-adjusted Cox regression models were fitted to assess associations between baseline serum calcium levels and onset of end-stage renal disease(ESRD) or death in patients with MM followed for > 6 months.Results: Using the IMWG criteria,162 of 566 patients (28.6%) with newly diagnosed MM presented with RI . The mean duration of follow-up was 26.64 months. Twenty-one patients (8.54%) died and 28 patients（11.52%）had ESRD.The serum calcium level was independently associated with the occurrence of MM-related RI. There was a non-linear relationship between the serum calcium level and the presence of RI in patients with MM in the cross-sectional analysis of the baseline data. Cox regression analysis showed that baseline serum calcium levels were consistently associated with a higher risk of all-cause death after adjustment for various clinical and laboratory factors, but were not associated with the occurrence of ESRD. When patients were categorized into 2 groups according to baseline mean serum calcium level, deaths occurred in 13 patients (15.1%) with mean serum calcium level > 2.44 mmol/L compared to 8 patients (5.0%) with mean serum calcium level < 2.44 mmol/L (p < 0.05); Eighteen patients (11.46%) with a mean serum calcium level < 2.44 mmol/L progressed to ESRD compared to 13 patients (11.6%) with a serum calcium level > 2.44 mmol/L (p > 0.05).Conclusions: This observational study showed that there was a non-linear relationship between the serum calcium level and the occurrence of RI. An elevated baseline calcium level can predict all-cause death in patients with MM, but cannot predict the occurrence of ESRD, suggesting that the serum calcium level may serve as a useful clinical biomarker for the survival rate of patients with MM followed for > 6 months. Additional data from larger prospective longitudinal studies are required to validate our findings.

Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis

2021 ◽  
Vol 41 (4) ◽  
pp. 827-831
Author(s):  
Min Li ◽  
Chen Jiang ◽  
Jing-wen Yang ◽  
Zao-qin Yu ◽  
Wei Li ◽  
...  
Keyword(s):  
Clinical Features ◽  
Chinese Patients ◽  
Hypersensitivity Reactions ◽  
Multicenter Analysis

Combination Therapy Based on Bortezomib for Newly-Diagnosed Multiple Myeloma: a Chinese Experience

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 5036-5036
Author(s):  
Li Yang ◽  
Jing-Song He ◽  
WenJun Wu ◽  
Xiujin Ye ◽  
Jimin Shi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Partial Response ◽  
Combination Therapy ◽  
Combination Chemotherapy ◽  
Chinese Population ◽  
Conflicts Of Interest ◽  
Malignant Neoplasm ◽  
Chinese Patients ◽  
Newly Diagnosed ◽  
Grade 3

Abstract Abstract 5036 Multiple myeloma (MM) is a malignant neoplasm of plasma. With conventional chemotherapy, the rates of complete remission (CR) or very good partial remission (VGPR) are still low. Little has been reported on Bortezomib-based therapies specifically in the Chinese pateitns with MM. Here we report our results with combination therapy based on bortezomib in the Chinese population. We investigated the efficacy and safety of Bortezomib-based therapies in previously untreated MM patients. Methods: Between June 2006 and June 2010, 61 consecutive newly-diagnosed patients with symptomatic MM were treated with combination therapies based on Bortezomib. Forty-two patients were male and 19 were female. Median age was 59 years (range 37–86 years). Forty-four patients were stage 3 according to the International Staging System, 6 patients were stage 2 and 11 patients were stage 1. The conbinations included dexamethasone, dexamethasone plus subsequent thalidomide and dexamethasone plus cyclophosphamide. In detail, Bortezomib was at the dose of 1.3 mg per square meter IV on days 1, 4, 8, 11 and dexamethasone at 20 mg per square meter IV daily on the day of bortezomib and the day after, with or without daily oral thalidomide that was escalated from 100 mg to 200 mg (BD group or BDT group) or plus cyclophosphamide at 0.2 per square meter IV on days 1 to days 4 (BDC group). Thirty-four patients were in BDT group, 12 in BD group and 15 in BDC group. All patients received a median of three cycles of therapy (range 1–6). The IMWG criteria were used for response evaluation and toxicities were evluated according to the NCI Common Toxicity Criteria version 3. Results: The proportions of patients with very good partial response (VGPR) or better were 38% (13/34), 25% (3/12) and 60% (9/15) in BDT, BD and BDC group, respectively; 44% (15/34), 33% (4/12) and 33% (5/15) achieved partial response (PR). Therefore the overall response (VGPR plus PR) were 82% (28/34), 58% (7/12) and 93% (14/15). Three patients died with severe infection without disease progression. Grade 3–4 toxicities included fatigue (4/34, 1/12 and 4/15), thrombocytopenia (8/34, 3/12 and 5/15), diarrhea (4/34, 2/12 and 2/15) and infection (7/34,3/12,6/15) in BDT, BD and BDC group, respectively. Grade 1–2 neuropathy were occurred in 20 patients (59%), 6 patients (50%) and 9 patients (60%) and grade 3–4 were occurred in 6 (18%), 1 (8%) and 1 (7%) in BDT, BD and BDC group, respectively. Herpes zoster occurred in 6 patients (18%), 1 patients (8%) and 2 patients (13%) respectively. Routine anticoagulation or anti-thrombsis were not used. Only 1 patient suffered from DVT/PE but did well with treatment. Conclusions: Our preliminary experience in Chinese patients indicated that combination chemotherapy based on Bortezomib is highly effective in newly-diagnosed multiple myeloma and BDC or BDT regimens may be more superior than BD in Chinese population. There were relative lower rates of grade 3–4 neuropathy and DVT/PE in the Chinese patients with MM receved combination chemotherapy based on bortezomib. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document